ALZHEIMER’S DISEASE THERAPEUTIC APPROACHES

SANDHYA A, GOMATHI KANNAYIRAM*
Department of Biotechnology, Dr. M.G.R. Educational and Research Institute, University, Chennai – 600 095, Tamil Nadu, India.
Email: gomathi.sbt@drmgrdu.ac.in

Received: 03 February 2018, Revised and Accepted: 06 April 2018

INTRODUCTION

Major unsolved problems in biochemistry are protein folding. It has been recognized as the most critical obscure in the current century, because of the complex protein structure, which makes it difficult in predicting the folding patterns correctly [1]. Abnormal protein fibrils of extracellular fibrous amyloid deposits or intracellular inclusions are characterized to many neurodegenerative diseases, including Alzheimer’s disease (AD), Parkinson’s disease (PD), Huntington disease, and human prion diseases [2]. Conformational diseases are classified into a large number of disorders, which occurs due to conformational changes in the protein misfolding [3,4]. Many diseases can be further subdivided based on the hereditary inclusion body myositis. To monitor the formation of protein structure, there is a specific strategy that uses a battery of complementary stopped - flow and quenched - flow techniques. The other method involves the use of temperature jumps under cold denaturation conditions in which increase in temperature leads to refolding [5]. Amyloidosis in incomplete protein folding due to a minor error in the genetic blueprint are the two major classifications of protein folding disorders. AD patients have more number of amyloid plaques with degenerative nerve endings; the counts of the plaques are more in number when compared to the normal aging person’s brain. This correlates with the type of mental impairment [7]. There are many flourishing evidences stating that accumulation of proteins which are capable of forming amyloid deposits is the pathological mechanisms of illness [8,9]. In protein aggregation, monomers interact with dimers, oligomers, and insoluble fibrillar deposits.

The role of soluble oligomers in protein aggregation is beta-amyloid protein in AD and alpha-synuclein in PD [2]. Imbalance between amyloid beta production and its clearance results in the formation of neurofibrillary tangles (NFTs) containing tau proteins, synaptic and neuronal loss, and neuroinflammation [10]. As AD, Type 2 diabetes mellitus (T2DM) is a degenerative metabolic disease which occurs in older age; there will be a gradual loss of insulin secretion in pancreatic beta cells. According to the current records, about 96% of T2DM patients are diagnosed of this disease [12]. Based on the current understanding there are a lot of therapeutic and diagnostic approaches on amyloid beta protein and alpha-synuclein pathobiology. Alpha-synuclein is found in the human brain at the tips of nerve cells. Gene is located on chromosome 4 in humans with band range 89,724, 099 bp–89, 838, and 315 bp [14]. Studies reveal that human alpha-synuclein is made up of 140 amino acids encoded by SNCA gene [6]. Similarly, research and elucidation of protein folding and aggregation in AD and T2DM have become the important focal points of pharmaceutical research, which enhances the probability of therapeutic and pharmacological tools for understanding.

As we know, neurodegeneration occurs due to the loss in function of neuron or neuron cell death. In all neurodegenerative diseases, the mechanism involved is a genetic mutation, in which repeat CAG triplet codes glutamine amino acid to form poly Q tract [13]. This study is conducted in animal models such as nematode, fruit fly, non-human pirates, and mice [10]. Several neurodegenerative diseases are proteopathies caused by protein misfolding [7]. This topic is a review on the clinical manifestations, diagnosis, risk factors, and treatment which can reform certain symptoms of illness.

WHAT IS AD? AND WHY IS IT CRIPPLING?

Alzheimer’s is the form of dementia, which means memory loss and other cognitive abilities [2]. In other words, it can be explained as progressive, degeneration of brain ailment which affects memory, behavior, and thinking. It is identified by Alois Alzheimer in the year 1906. There are about 60–80% dementia cases. In the UK, currently, 5.5 million of ages 65 are more prone to this disease. According to the report in 2005 more than 24 million people are affected worldwide; an increase with 4.6 million of new cases each year. In recent 2017 report, 5.5 million people are reported with Alzheimer’s [15]. In India more than 4 million people suffer from dementia, Alzheimer’s seems to be more common condition out of all who have been affected. In some statistical report, they found that Alzheimer’s may set to become a triple by 2050. Average duration of this disease is about 8 years but can past up to 20 years. The survival rate of the patient depends on the onset of the disease symptoms.

Early onsets of AD are the rarest that accounts only in 2% of cases approximately between the age group of 30 and 60 years. The occurrence is due to the genetic inheritance patterns in case of the later onset and due to high genetic predisposition which involves in gene polymorphisms [2]. Identifying the genetic factors that predispose AD is a much difficult process.
There are four different stages in Alzheimer’s - mild, moderate, and severe. Tau proteins stabilize microtubules which have a critical function in cell division and intracellular trafficking [5].

**NEUROPATHOLOGIC HALLMARK OF AD**

The Alzheimer is a syndrome of neuropathological hallmark. The changes that occur in the neuritic plaques shows to be the major mark of extracellular amyloid deposition and also the NFTs which acquire the intracellular accumulation of tau protein which is to be seen by hyperphosphorylated (Fig. 3) [21]. The AD and PD are associated with defective tau proteins which lack the stabilizing capacity of microtubules. These tau proteins are the product of different splicing from a single gene. In humans, it is designated as microtubule-associated protein tau which is located on chromosome 17 [5] and in mouse chromosome 11. Tau proteins are identified as heat stable proteins in 1975.

Large randomized clinical trials evaluate anti-amyloid and disease-based therapies for the treatment and prevention of AD. This therapy utilizes imaging biomarkers. NFTs involved are known as Braak stages. In Pick’s disease and corticobasal degeneration, tau proteins which stabilize microtubules are deposited as inclusion bodies within swollen neurons. Sometimes, the synuclein and tau protein interaction causes overlapping of tauopathies with synucleinopathies.

Amyloid precursor protein (APP) metabolic pathway. Neurobiological mechanisms involved in the pathogenesis of AD (Fig. 1).

Hence, the tau protein plays a major role in memory deficits in AD amyloid-beta alters the tau metabolism and leads to disease. Based on amyloid beta hypothesis, amyloid beta is derived from the APP by two aspartyl proteases: Beta- and gamma-secretases [16]. Beta-secretase cleaves APP to remove the larger ectodomain by leaving the C-terminal stub which is membrane bound. Concomitantly, gamma-secretase cleaves 99 amino acid stub and releases an amyloid beta [17]. Relying on the gamma-secretase, the amyloid beta comprises into 40 and 42 amino acid residues. Longer form of amyloid-beta which is prone to oligomerize forms fibril resulting in the formation of amyloid beta 40 and 42. When compared to amyloid beta 42, amyloid beta 40 is involved in fibril formation, overproduction of amyloid beta 42 results in early onset of AD [18].

It is the primary structure of the β-APP, comprising 770 amino acids. At the N terminal, 17 residue signal peptide occurs and two alternatively spliced exons of 56 and 19 amino acids are inserted at 289 residues containing serine protease inhibitor as the first domain of Kunitz type. 542 and 571 are found as N-glycosylation sites. The vertical orange bar contains membrane-spanning domain amino acids 700–723. The amyloid β protein fragment is represented as a white box containing 28 residues, 12–14 residues are on the outer membrane as a transmembrane domain. The residue 687 is indicated with an arrow is a constitutive proteolytic cleavage which is made by unknown proteases designated as α-secretase, which enables secretion of the large, soluble ectodomain of APP into the medium and the retention of the β3-residue carboxy-terminal fragment in the membrane which is approximately 10kDa, this fragment can undergo cleavage at the residue 711 or 713 by unknown protease known as γ-secretase and releases the p3 peptides. The residue 671 is cleaved by an unknown proteolytic enzyme called as β-secretase, resulting in the secretion of truncated APP, molecule which has the retention of 99-residue of approximately 12 kDa (carboxy-terminal fragment). Further, the cleavage of 12 kDa fragment is carried by γ-secretase, which further releases Aβ peptides. Besides age, the terminal fragment). Further, the cleavage of 12 kDa fragment is carried by γ-secretase, which further releases Aβ peptides. The beta hypothesis, amyloid beta is derived from the APP by two aspartyl proteases: Beta- and gamma-secretases [16]. Beta-secretase cleaves APP to remove the larger ectodomain by leaving the c-terminal stub which is membrane bound. Concomitantly, gamma-secretase cleaves 99 amino acid stub and releases an amyloid beta [17].

Amyloid beta 42 results in early onset of AD [18].

It is the primary structure of the β-APP, comprising 770 amino acids. At the N terminal, 17 residue signal peptide occurs and two alternatively spliced exons of 56 and 19 amino acids are inserted at 289 residues containing serine protease inhibitor as the first domain of Kunitz type. 542 and 571 are found as N-glycosylation sites. The vertical orange bar contains membrane-spanning domain amino acids 700–723. The amyloid β protein fragment is represented as a white box containing 28 residues, 12–14 residues are on the outer membrane as a transmembrane domain. The residue 687 is indicated with an arrow is a constitutive proteolytic cleavage which is made by unknown proteases designated as α-secretase, which enables secretion of the large, soluble ectodomain of APP into the medium and the retention of the β3-residue carboxy-terminal fragment in the membrane which is approximately 10kDa, this fragment can undergo cleavage at the residue 711 or 713 by unknown protease known as γ-secretase and releases the p3 peptides. The residue 671 is cleaved by an unknown proteolytic enzyme called as β-secretase, resulting in the secretion of truncated APP, molecule which has the retention of 99-residue of approximately 12 kDa (carboxy-terminal fragment). Further, the cleavage of 12 kDa fragment is carried by γ-secretase, which further releases Aβ peptides. Besides age, the terminal fragment). Further, the cleavage of 12 kDa fragment is carried by γ-secretase, which further releases Aβ peptides. The beta hypothesis, amyloid beta is derived from the APP by two aspartyl proteases: Beta- and gamma-secretases [16]. Beta-secretase cleaves APP to remove the larger ectodomain by leaving the c-terminal stub which is membrane bound. Concomitantly, gamma-secretase cleaves 99 amino acid stub and releases an amyloid beta [17].

Amyloid beta 42 results in early onset of AD [18].

It is the primary structure of the β-APP, comprising 770 amino acids. At the N terminal, 17 residue signal peptide occurs and two alternatively spliced exons of 56 and 19 amino acids are inserted at 289 residues containing serine protease inhibitor as the first domain of Kunitz type. 542 and 571 are found as N-glycosylation sites. The vertical orange bar contains membrane-spanning domain amino acids 700–723. The amyloid β protein fragment is represented as a white box containing 28 residues, 12–14 residues are on the outer membrane as a transmembrane domain. The residue 687 is indicated with an arrow is a constitutive proteolytic cleavage which is made by unknown proteases designated as α-secretase, which enables secretion of the large, soluble ectodomain of APP into the medium and the retention of the β3-residue carboxy-terminal fragment in the membrane which is approximately 10kDa, this fragment can undergo cleavage at the residue 711 or 713 by unknown protease known as γ-secretase and releases the p3 peptides. The residue 671 is cleaved by an unknown proteolytic enzyme called as β-secretase, resulting in the secretion of truncated APP, molecule which has the retention of 99-residue of approximately 12 kDa (carboxy-terminal fragment). Further, the cleavage of 12 kDa fragment is carried by γ-secretase, which further releases Aβ peptides. Besides age, the terminal fragment). Further, the cleavage of 12 kDa fragment is carried by γ-secretase, which further releases Aβ peptides. The beta hypothesis, amyloid beta is derived from the APP by two aspartyl proteases: Beta- and gamma-secretases [16]. Beta-secretase cleaves APP to remove the larger ectodomain by leaving the c-terminal stub which is membrane bound. Concomitantly, gamma-secretase cleaves 99 amino acid stub and releases an amyloid beta [17].

Amyloid beta 42 results in early onset of AD [18].

It is the primary structure of the β-APP, comprising 770 amino acids. At the N terminal, 17 residue signal peptide occurs and two alternatively spliced exons of 56 and 19 amino acids are inserted at 289 residues containing serine protease inhibitor as the first domain of Kunitz type. 542 and 571 are found as N-glycosylation sites. The vertical orange bar contains membrane-spanning domain amino acids 700–723. The amyloid β protein fragment is represented as a white box containing 28 residues, 12–14 residues are on the outer membrane as a transmembrane domain. The residue 687 is indicated with an arrow is a constitutive proteolytic cleavage which is made by unknown proteases designated as α-secretase, which enables secretion of the large, soluble ectodomain of APP into the medium and the retention of the β3-residue carboxy-terminal fragment in the membrane which is approximately 10kDa, this fragment can undergo cleavage at the residue 711 or 713 by unknown protease known as γ-secretase and releases the p3 peptides. The residue 671 is cleaved by an unknown proteolytic enzyme called as β-secretase, resulting in the secretion of truncated APP, molecule which has the retention of 99-residue of approximately 12 kDa (carboxy-terminal fragment). Further, the cleavage of 12 kDa fragment is carried by γ-secretase, which further releases Aβ peptides. Besides age, the terminal fragment). Further, the cleavage of 12 kDa fragment is carried by γ-secretase, which further releases Aβ peptides. The beta hypothesis, amyloid beta is derived from the APP by two aspartyl proteases: Beta- and gamma-secretases [16]. Beta-secretase cleaves APP to remove the larger ectodomain by leaving the c-terminal stub which is membrane bound. Concomitantly, gamma-secretase cleaves 99 amino acid stub and releases an amyloid beta [17]. Relying on the gamma-secretase, the amyloid beta comprises into 40 and 42 amino acid residues. Longer form of amyloid-beta which is prone to oligomerize forms fibril resulting in the formation of amyloid beta 40 and 42. When compared to amyloid beta 42, amyloid beta 40 is involved in fibril formation, overproduction of amyloid beta 42 results in early onset of AD [18].

Pick’s disease occurs when the non-Alzheimer’s tauopathies get associated with frontotemporal dementia [11]. Extracellular amyloid plaques and NFTs show the presence of Alzheimer’s in the brain [6]. They exhibit morphological and biochemical characteristics. Neurons bear NFTs, composed of hyperphosphorylated microtubules associated protein, known as tau [11]. Not only Alzheimer’s are associated with NFTs but with other disorders which are not associated with cognitive dysfunction and memory impairment. Recent study stated that tau phosphorylation is the limiting factor in amyloid-beta-induced neurotoxicity.

The brain of Alzheimer’s patient is characterized microscopically, by the extracellular amyloid plaques and intraneuronal NFTs. The numerous proteins in amyloid plaques have a broad range of morphological and biochemical characteristics [47,48]. Plaques those are diffused are not tending to be fibrillar and have Aβ<sub>40</sub>. These are the immature deposits which are detected in the younger patient’s brain along with Down’s syndrome before AD manifestations. As a result of this, the diffuse plaques are considered to be the precursors to mature into neurotic plaques. Few plaques such as dilated, dystrophic neurites, activated microglia, and reactive astrocytes can be seen around the neuritic plaques [49].

AD involves risk factors such as modifiable and non-modifiable. Modifiable includes diet, supplementary intake, T2DM, mood, and hypertension whereas non-modifiable includes genes and family history. The major cause of AD is vascular factors. Smoking involves the cardiac risk, those who consume alcohol accumulates a lot of risk associated with brain atrophy and volume loss. Similarly, obesity leads to dementia and cerebral damage [50].

As we discussed above, there are many significant literature which supports every process and clearance of Aβ, which is found to be the major component of amyloid plaques [52-57]. As well when compared
The most prevalent problem in aged people is AD and T2DM. As discussed, the cerebral Aβ accumulation is the pathological hallmark in the AD [81], it is because of the deposition of the different polypeptide, known as amylin, that gives in the β-sheet formation and self-aggregation in the pancreas, mainly within the β-cells, of T2DM [82]. Many studies have reported that T2DM causes pathological angio genesis and immature vascularization [83]. In some, it even leads to chronic cerebral hypoperfusion results in neuro-gial dysfunction and also degeneration [84]. Many suffering from T2DM are prone to attacks, often silent produces major consequences such as dementia and other long-term problems [85]. This kind of dementia accompanies in vascular dysfunction and known as a vascular cognitive impairment [86]. Aβ in the normal brain of a person is dispersed in an excitation-dependent manner and have many physiological functions [87,88]. If we have a healthy vascular system, it will aid in proper function, but it will be critical when oligomerization and deposition of Aβ starts. Neuroinflammation along with the process of seeding and spread is initiated eventually with neuronal dysfunction, and toxicity ensue [89]. With the event of insulin resistance, defective insulin signaling, and also the mitochondrial dysfunction in the brain, which are the common quirks of T2DM and AD; hammering the questions which one leads the other in the aged people [90-92].

Genetic linkage studies are identified as an AD that is susceptible to focus on chromosome 19 which is been shown in the ApoE gene [94]. Normally, in man, ApoE gene exhibits in three polymorphisms and some population studies demonstrate that there is an increase in the frequency of the E4 isofrom in many AD patients [95].

TDP2M AND AD LINKAGE

DM is a metabolic disorder, which shows higher blood glucose levels for a long period of time and loss of homeostasis (glucose). T2DM occurs due to the lack of insulin, whereas in T2DM there will be a demand of insulin in pancreatic β cells which will be insufficient [71]. Those people, who suffer with T2DM, are prone of higher risk of vascular dysfunction, loss in vision, impairments of cognitive function and kidney function deficiencies which result in dialysis [72,73]. Same as non-directed donors, T2DM occurs at later age. There are certain biochemical defects in T2DM, which is a protease enzyme that comprises of IAPP but in major T2DM patients they are found to be absent [74]. IAPP, a part of calcitomin - like a family of polypeptides and is seen in animal species. It does not form amyloid in all species, but they are amyloidogenic in humans. IAPP is a derived from an 89 aa pre-prohormone [75,76].

There is a vast difference between amyloidogenic human IAPP, and the non-amyloidogenic rat polypeptide is the amino acid change will be at the 6th position. Within the two terminal part of polypeptides, there occurs a conserved a region which is the main components and plays a key roles. The former part is known to get involved in activating the receptor, and the latter part binds in an antagonistic manner. There will a middle domain between these two parts differentiates the IAPP in different forms and is responsible for aggregation at different propensities. When considered a rat model, the IAPP comprises 3 prolines. The β-sheet formation gets affected by the proline and N-methyl amino acids. The mid-region has a single point of mutation and a Ser20Gly substitute, which promotes the amyloid formation and causes β-cell death [77].

Patients with higher blood sugar level have their β cells would secrete elevated levels of insulin along with the IAPP, and there will be shift in lipid metabolism, that converts the excess amount of glucose into lipids, which would stress the system. The excess free radicals provide the ability to disrupt the charge and further the confirmation of the native proteins and the mechanism of clearance, therefore, the folding and modifying would turn to be a pathological role from the physiological [78,80].

DIAGNOSTIC METHODS OF AD

There is no specific test which confirms the Alzheimer’s in the people. Certain diagnostic methods such as physical examination along with the mental status and neuropsychological testing are the first line treatment that can be given to the patients with AD. The disease prevention is inevitable. Therefore, the progress is measured using mini mental scale examination and Montreal Cognitive Assessment (MoCA) and clinical dementia rating scale. The measurements obtained from such scales are not so linear and showed a decline in the studies of the patients. Many clinicians use the standardized mental scale for the measurement, but compared to all MoCA with cutoff score 26 is widely used for the measurement of the patients mental status due to its sensitiveness for execution and language dysfunction.

Few diagnostic tools such as the brain imaging techniques - magnetic resonance imaging (MRI), computed tomography, positron emission tomography (PET), and cerebrospinal fluid (CSF) are currently used which may enable doctors to detect any specific changes caused due to AD. Brain MRI can document the structural diseases and the regional fentemorial dementia. In case of structural MRI, the findings include focal atrophy and white matter lesions [21]. As these findings are nonspecific, the hippocampal volumes are considered to be the focal findings of the AD patients, because the hippocampal volume decline in normal aging and provides an evident support to the AD patients [24].

Nowadays, the AD neuroimaging is made available with the help of the hippocampal volumetry using age-related norms. The distinct region of the low metabolism and hypoperfusion of AD patients are revealed by functional brain imaging with fluorodeoxyglucose PET, functional MRI, and perfusion MRI [21]. Amyloid PET tracers such as...
Donepezil, galantamine, and rivastigmine are the three different therapeutic approaches for the treatment of AD (Fig. 4). These medications are used to treat patients with mild to moderate AD. The cholinesterase inhibitors provide clinical benefit in patients with AD. However, they do not cure the disease. They improve memory and cognitive function, and they may also slow the progression of the disease.

In recent research, they developed a thioflavin T analog, which is a Pittsburgh compound-B (PIB) compound B, which binds to β-sheet that is rich in fibrils. This compound crosses blood-brain barrier and binds to amyloid deposits in the brain parenchyma. This result in detecting in vivo and progresses the development of the anti-amyloid drugs which help to differentiate AD from dementia.

Cholinesterase inhibitors are widely used treatments that are made available for the patients. It is a symptomatic medication for the cognition and global functioning in patients. The inhibitor targets the acetylcholine deficit and raises the loss of neurons in the nucleus basalis of Meynert. In majority cases, the patients who are diagnosed with AD are offered with symptomatic treatment (cholinesterase inhibitors) which is been conducted as a trial of treatment. It is suggested to most of the patients with dementia and with lewy bodies and has greater benefits in patients. The degree of benefit using cholinesterase inhibitors is studied in the patients of various severities [25-27].

THERAPEUTIC APPROACHES IN AD CASES
Different therapeutic approaches for the treatment of AD (Fig. 4).

Cholinesterase inhibitor
The cholinesterase inhibitors and memantine are the widely used treatments that are made available for the patients. It is a symptomatic medication for the cognition and global functioning in patients. The inhibitor targets the acetylcholine deficit and raises the loss of neurons in the nucleus basalis of Meynert. In majority cases, the patients who are diagnosed with AD are offered with symptomatic treatment (cholinesterase inhibitors) which is conducted as a trial of treatment. It is suggested to most of the patients with dementia and with lewy bodies and has greater benefits in patients. The degree of benefit using cholinesterase inhibitors is studied in the patients of various severities [25-27].

<table>
<thead>
<tr>
<th>Stages of dementia</th>
<th>MMSE</th>
<th>MoCA</th>
<th>CDR</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mild</td>
<td>19–26</td>
<td>12–16</td>
<td>1</td>
</tr>
<tr>
<td>Moderate</td>
<td>10–18</td>
<td>4–11</td>
<td>2</td>
</tr>
<tr>
<td>Severe</td>
<td>&lt;10</td>
<td>&lt;4</td>
<td>3</td>
</tr>
</tbody>
</table>

CDR: Clinical dementia rating, MoCA: Montreal cognitive assessment, MMSE: Mini-mental state examination

The relative effects of the cholinesterase inhibitors appear to be similar with the severe dementia patients. In earlier stages, short-term trials using donepezil or galantamine are used in moderate to advanced dementia. Donepezil, galantamine, and rivastigmine are the three different variety formulations of cholinesterase inhibitors. Donepezil hydrochloride 5 mg daily at first and then 10 mg daily; rivastigmine 1.5 mg twice daily at first; and then 6 mg twice daily; galantamine 4 mg twice daily; and then 12 mg twice daily. Recent studies indicate that donepezil reduces memory and cognitive loss during early for several months [28,29]. The cholinesterase inhibitor provides clinical benefit only when the patients exhibit behavioral and psychological symptoms, and it is not found to be the preventive measure.

Memantine
FDA approved memantine, an antagonist for treating moderately advanced AD. It reduces the potential of glutamatergic excitotoxicity. The drug is prescribed as 5 mg daily and increased to 5 mg twice daily and then to 10 mg twice daily. A studied showed that the patients are taking stable doses of donepezil, memantine had better outcome. However, these appropriate results show to be better outcome only when it is administered with cholinesterase inhibitor [30].

Hormone replacement therapy
According to the report given by women’s health initiative study of estrogen and medroxyprogesterone in a postmenopausal women have higher chance of dementia. Estrogen therapy has adverse effect in women aged 65 years [31]. Similarly, it is found that estrogen therapy alone did not reduce dementia or incidence of mild cognitive impairment, but it also increases the risk of both conditions in a combined form. Therefore, hormone therapy used to prevent dementia showed a decline rate in 65 years women or older and is not recommended [32].

**Fig. 1:** Obtained from international journal of gerontology “new therapeutic targets in Alzheimer’s disease”

**Fig. 2:** Obtained from NCBI article “Alzheimer’s disease is the most common neurodegenerative disorder”

F18 - florbetapir, F18 - flutemetamol, and F18 - florbetaben are used to measure the amyloid lesion burden in the brain which is aimed to be the tool to diagnose AD in vivo and progresses the development of the anti-amyloid drugs which help to differentiate AD from dementia.

Certain biomarkers which are not used in routine diagnostics play a major role in supporting AD by investigating the molecular and degenerative process. Low CSF Aβ42, positive amyloid PET imaging using one of the amyloid PET tracers is the molecular biomarkers of Aβ protein deposition [22]. Biomarkers of tau deposition which is a key component of NFTs are increased CSF total tau and phospho tau and evidence of cerebral tau using a tau-specific PET tracer which is in development. Topographic biomarkers are used to assess the downstream brain changes which correlate with the neuronal dysfunction and neuronal death which associates AD [23].

Certain lab tests are recommended by the clinicians such as hypothyroidism and Vitamin B12 deficiency. Testing for infectious diseases such as syphilis and human immunodeficiency virus should be collected under suitable clinical circumstances. Mostly, PET allows visualizing the metabolism in most of the brain regions using 11C-2-deoxy-2-[fluoro-D-glucose (FDG) which serves as a surrogate marker of glucose metabolism. In some patients, early AD decreases the metabolism in parietal-temporal associates with the cortex and the cingulate gyrus and some marked changes in the medial temporal region and parietal-temporal that associates with cortex are detected. In abnormal PET-FDG is marked in the frontal which is associated with cortex. In accordance with the changes that are detected in regional cerebral perfusion by a single photon emission that computes with SPECT and can distinguish mild AD and various form of vascular dementia [99].

In recent research, they developed a thioflavin T analog, which is a Pittsburgh compound-B (PIB) compound B, which binds to β-sheet that is rich in fibrils. This compound crosses blood-brain barrier and binds to amyloid deposits in the brain parenchyma. This result in detecting the Carbon-11 which is labeled with PIB [100].

**Sandhya and Kannayiram**
Antioxidants
A randomized study was conducted using selegiline, Vitamin E, and both together in patients with AD and compared with placebo [33]. This trial showed a positive result when compared to placebo. One of the other studies stated that Vitamin E at 2000 international units a day slows the progress of the disease. Cochrane dementia group register of clinical trials found that there is no sufficient evidence for the efficacy of Vitamin E in the AD treatment [34].

Anti-inflammatory drugs
AD patients have minor cellular signs of inflammation, increased cytokines and interleukins. The anti-inflammatory drugs such as naproxen and rofecoxib resulted with 1 year change in AD assessment scale-cognitive subscale score. These drugs did not reduce the cognitive loss. Since the drugs resulted in failure, clinical trial with an anti-inflammatory agent is still an incomplete finding [35,36].

Cholesterol lowering therapy
Statins, HMG CoA is the reductase inhibitors, for preventing AD. HMG CoA has a low risk of developing dementia. A randomized trial with statins was conducted by simvastatin or atorvastatin in hypercholesterolemia patients. Using this drug plasma level of Aβ40 and Aβ42 is measured. Both stains reduced 56% of plasma levels but the levels of Aβ40, Aβ42, and total Aβ unchanged. These studies did not support the effect of statins and alter the APP processing in humans [37,38].

Vaccination
Aβ42 is given as monthly immunization for 11 months, prevents the Aβ plaque formation, neuritic dystrophy, and astrogliosis. The astrogliosis in mice is transferred with V717F human APP gene which is mutant. The Aβ42 generates antibodies, recognizes Aβ plaques, diffuse Aβ deposits, and vascular Aβ in blood vessels of brain. This concludes that Aβ42 have higher degree of selection which targets the pathogenic structures.

Even though Aβ42 revealed itself to be a positive therapeutic effect, they induced the immunized patients to develop autoimmune meningoencephalitis. In some cases, the brain of people having mild to
APP metabolic pathway. APP = AMYLOID PRECURSOR PROTEIN; Aβ = APP by the inhibition of secretases [43]. prevented by Aβ42 reduction which is involved in the metabolism of releases Aβ40, Aβ42, and Aβ43 [42]. with the 91 amino acid - long peptide chain, cleaved by γ-secretase and with 83 amino acid - small peptide chain. Further, this smaller chain is cleaved by γ-secretase to produce two amyloidogenic peptides. Three secretases are the key action for APP metabolic pathway. The APP cleaving enzyme which cleaves at specific β site is a direct protease, found to be a predominant β-cleavage activity in brain. The APP clearing enzyme which cleaves at specific β site is a direct approach in developing pharmacologic agents, which, in turn, inhibits gene expression. γ-secretase inhibition provides a specific target in inhibiting Aβ synthesis. γ, β inhibition prevents the Aβ synthesis and also affects the formation of plaques (Fig. 5) [40,41].

Clioquinol In a pilot study in patients with AD metal chelation using clioquinol is reported to reduce the rate of cognitive loss in phase 2 clinical trials. It chelates amyloid plaques associated zinc and copper. The basic therapeutic treatment is the mobilization and removal of brain amyloid [45].

Dietary supplements Vitamin B1 is a supplement, involved in homocysteine metabolism which slows down the progression of AD. Randomized trial showed no effect on cognitive measures. Omega-3-fatty acids along with intake of fish lower the risk of dementia [44].

Strategies of anti-amyloid Three secretases are the key action for APP metabolic pathway. The non-amyloid metabolizes involves the proteolysis of APP under the influence of α-secretase and forms a soluble fragment α-APP along with β3 amino acid - small peptide chain. Further, this smaller chain is cleaved by γ-secretase to produce two amyloidogenic peptides. Simultaneously, amyloid metabolizes involve the proteolysis of APP using β-secretase [79]. The resulting fragment is called as β-APP along with the 91 amino acid - long peptide chain, cleaved by γ-secretase and releases Aβ40, Aβ42, and Aβ43 [42]. The anti-amyloid immunotherapy and amyloid aggregation are prevented by Aβ42 reduction which is involved in the metabolism of APP by the inhibition of secretases [45].

APP metabolic pathway: APP = AMYLOID PRECURSOR PROTEIN; Aβ = AMYLOID-BETA; PROTEIN FRAGMENTS = 48/49/51, B3, 91, p3, p7. The mutations of APP by FAD gets clustered around the α, β, and γ-secretase cleavage sites which induce a change phenotypically while processing the APP and results in increase of Aβ peptide [46].

siRNA gene therapy The APP accumulation is the major cause of AD. The APP gene nucleotide sequence is targeted using Accelyrs Gene software to silence the APP gene. pAZLDC1 vector is an efficient treatment of AD [51].

Aβ-based therapies The production of soluble Aβ monomer is decreased, and the soluble and deposited Aβ is removed. This reduction is attractive because of it; they can be easily titrated down to various concentrations which will not support oligomerization. This production of Aβ from APP forms oligomers and fibrils that have potential targets for anti-amyloid therapies [95].

Other therapeutic approaches There are few other therapeutic approaches which shows the results in the treatment of AD. They are: nerve growth factor stimulation, gamma amino butyric acid receptor modulators, serotonin receptor and somatostatin secretion stimulants, astrocyte modulating agents, phosphodiesterase 4 inhibitors, and cannabinoid agonists.

CONCLUSION All the neurodegenerative diseases are age prevalent disorders that occur in many individuals commonly nowadays occurs due to the changes in the molecular mechanisms. There are a lot of evidences for neurodegenerative diseases, arising from oligmeric productions for characterization of diseases, such as AD, PD, and T2DM. Proteins such as amyloid-beta and alpha-synuclein are deleterious to neurons which cause damage to the molecular mechanism. Accumulation of misfolded proteins is associated to human diseases. Protein aggregation lacks the active conformation. In modern inventions elucidating protein misfolding has become the impact for the array of diseases and pathogenesis.

Therapies are likely to be a preventive measure because oligomers grow to form deposits of amyloid fibrils. This assemblies forming is stopped by various diagnostic tools, detecting these fibrils when a patient or an individual suffers with neurodegenerative diseases. Cholinesterase inhibitors are suggested to patients with dementia along with Lewy bodies and have greater symptomatic benefits in AD patients. The therapy is not continued in patients who do not appear to be benefiting.

The inhibition of sites in the process is carried out using Aβ is the most challenging therapeutic research. However, anti-Aβ immunotherapy, small molecule secretase inhibitors will be safer therapeutic approach for slowing the progression of disease. Taking into the consideration, the protein - misfolding has been the hot spring for modern scientific investigation, and it impacts the various pathogenesis of wide range of diseases, which includes AD and T2DM.

Including a lot of therapeutic approaches for the treatment of AD, seems to be giving a symptomatic therapy which is not believed to be neuroprotective for the underlying disease trajectory.

ACKNOWLEDGMENTS We thank DR. M.G.R. Educational and Research Institute for providing us the facilities and their support.

AUTHORS CONTRIBUTION Sandhya A contributed for the collection of the article, preparation of manuscript and revising the article. Dr. Gomathi Kannayiram contributed toward revising the article and for the intellectual content. All the authors gave approval for the manuscript.

CONFLICTS OF INTEREST None of the authors have any conflicts of interest on this article.
REFERENCES

Oxidative damage to DNA in diabetes mellitus. Lancet. Binding of human apolipoprotein E to... Association of apolipoprotein E 76.
78.
De Felice FG, Ferreira ST. Inflammation, defective insulin signalling, and mitochondrial dysfunction as common molecular denominators connecting Type 2 diabetes to Alzheimer disease. Diabetes 2014;63:2262-72.